Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: A prospective, randomized, single-blind, placebo-controlled clinical trial

Stefano Palomba, Tiziana Russo, Francesco Orio, Libuse Tauchmanovà, Errico Zupi, Pier Luigi Benedetti Panici, Carmine Nappi, Annamaria Colao, Gaetano Lombardi, Fulvio Zullo

Research output: Contribution to journalArticle

Abstract

Background: Raloxifene hydrochloride is a synthetic non-steroidal drug used for the prevention and treatment of post-menopausal osteoporosis. Pre-clinical and clinical data have shown that raloxifene may have a beneficial effect on leiomyomas. The aim of this prospective single-blind, randomized, placebo-controlled clinical trial was to evaluate the effectiveness of the addition of raloxifene to GnRH analogues on uterine, leiomyoma, and non-leiomyoma sizes, and on the occurrence of leiomyoma-related symptoms. Methods: After randomization using a computer-generated list, 100 pre-menopausal women with symptomatic uterine leiomyomas received either leuprolide acetate depot plus raloxifene 60 mg daily (group A) or leuprolide plus placebo tablet (group B) for six cycles of 28 days. At baseline and after treatment, uterine, leiomyoma and non-leiomyoma sizes, and leiomyoma-related symptoms were evaluated for each woman. Analysis was intention-to-treat method. Results: After six cycles of treatment, a significant decrease in uterine, leiomyoma, and non-leiomyoma sizes was detected in both groups in comparison with baseline. At the same time, no significant difference in uterine and non-leiomyoma sizes was observed between the groups. Leiomyoma sizes were significantly (P <0.05) lower in group A than in group B. No difference was observed in leiomyoma-related symptoms between groups throughout the study period. Conclusions: In women treated with GnRH analogue, the raloxifene administration induces a higher reduction of leiomyoma sizes.

Original languageEnglish
Pages (from-to)3213-3219
Number of pages7
JournalHuman Reproduction
Volume17
Issue number12
Publication statusPublished - Dec 1 2002

Keywords

  • Add-back therapy
  • Fibroids
  • GnRH analogue
  • Leiomyomas
  • Raloxifene

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: A prospective, randomized, single-blind, placebo-controlled clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Palomba, S., Russo, T., Orio, F., Tauchmanovà, L., Zupi, E., Panici, P. L. B., Nappi, C., Colao, A., Lombardi, G., & Zullo, F. (2002). Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: A prospective, randomized, single-blind, placebo-controlled clinical trial. Human Reproduction, 17(12), 3213-3219.